GET DAILY SIGNALSWhy Is Accuray Incorporated (ARAY) Stock Down -24.14% Today?
Key Takeaways
- Accuray shares fell 24.14% to $0.1131 in midday trading, down from a previous close of $0.1491, confirming a sharp downward move.
- Primary catalyst: fiscal Q1 2027 results missed on the top line, with revenue of $86.5 million versus a roughly $95.8 million consensus estimate.
- Secondary driver: the company announced a 1-for-40 reverse stock split, effective November 9, to restore Nasdaq minimum-bid compliance.
- Broader context: persistent China demand weakness and tariff headwinds continued to pressure product sales and gross orders.
- What traders are watching next: the reverse-split implementation and any sign of an order-momentum recovery.
- For deeper context on valuation and expectations, explore Price Targets, Earnings, and Forecast pages for this ticker.
- Interested in automated trading strategies? Explore Trending AI Robots.
Opening Summary
Accuray Incorporated (ARAY), a radiation oncology company best known for its CyberKnife and TomoTherapy treatment systems, fell sharply on Wednesday after reporting fiscal 2027 first-quarter results and disclosing a reverse stock split. Shares dropped 24.14% to $0.1131 in midday trading, down from a prior-session close of $0.1491. The move lower was driven primarily by a revenue miss and weak product orders, compounded by a 1-for-40 reverse split designed to keep the stock listed on the Nasdaq.
Fiscal Q1 2027 Results Miss on the Top Line
Accuray (ARAY) reported first-quarter fiscal 2027 revenue of $86.5 million, below the roughly $95.8 million consensus and down 8% year over year. Product revenue fell 26% to $27.3 million with only 12 systems shipped, while gross product orders dropped to $19.8 million, producing a book-to-bill ratio of 0.7 — well below the company's target of about 1.2. Although GAAP earnings per share of $0.07 topped the -$0.07 consensus, that figure was inflated by a $59.6 million non-cash gain on debt extinguishment. Excluding one-time items, the company posted a net loss of roughly $14.0 million, or $0.10 per share, and recorded a $35.4 million non-cash goodwill impairment charge.
Reverse Stock Split Signals Nasdaq Compliance Push
Compounding the earnings reaction, Accuray's board approved a 1-for-40 reverse stock split effective November 9, 2026. The move is aimed at lifting the share price above the $1.00 Nasdaq minimum-bid threshold, a step that underscores the distressed valuation and the delisting risk that has lingered since the company transferred to the Nasdaq Capital Market in August 2026. Reverse splits frequently trigger near-term selling pressure as investors reassess share counts and the underlying fundamentals.
China Demand and Tariff Headwinds Persist
Accuray (ARAY) has repeatedly cited geopolitical and tariff pressures in China — historically a key growth market — as a drag on product orders and revenue timing. Management said commercial activity in China remained slow amid tender, quota, and financing process delays, and the quarter included no CyberKnife shipments. The service business remained a bright spot, with service revenue up 4% to $59.2 million and an installed base now above 1,100 systems supporting more than $230 million in recurring annual revenue.
Market Context and Trading Activity
The decline was idiosyncratic rather than sector-driven, diverging from a broader Nasdaq that has posted double-digit gains in 2026. Trading activity reflected heavy repositioning around the dual earnings and reverse-split announcements. The stock remains in a pronounced downtrend, trading well below its 50-day moving average of about $0.22 and its 200-day moving average of about $0.36, and down roughly 89% over the trailing 12 months. With a market capitalization near $18 million, the shares remain highly volatile and sensitive to headline risk.
What Comes Next for ARAY
Investors now focus on the reverse split's effective date of November 9 and whether the post-split price can sustain above $1.00. Key watch items include the pace of order recovery, particularly in China, execution of the company's cost-transformation program, and the impact of its TCW financing, which includes a $40 million debt-for-preferred-equity exchange and a $15 million equity investment. Management has not provided formal fiscal 2027 revenue or adjusted-EBITDA guidance, adding to uncertainty. Risks include continued product-demand softness, potential dilution from preferred equity, and the possibility that the reverse split fails to durably restore listing compliance.
Trending AI Robots
Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving investors a range of automated approaches to explore. To see which strategies are currently leading the market, visit Trending AI Robots.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ARAY's RSI Indicator recovers from oversold territory
The RSI Oscillator for ARAY moved out of oversold territory on October 29, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 47 similar instances when the indicator left oversold territory. In 41 of the 47 cases the stock moved higher. This puts the odds of a move higher at 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on ARAY as a result. In 78 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for ARAY just turned positive on November 02, 2026. Looking at past instances where ARAY's MACD turned positive, the stock continued to rise in 40 of 48 cases over the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
ARAY moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ARAY crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 76%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARAY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for ARAY entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.427) is normal, around the industry mean (4.338). P/E Ratio (-0.373) is within average values for comparable stocks, (1.324). Projected Growth (PEG Ratio) (2.060) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (0.070) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. ARAY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of medical equipment
Industry MedicalNursingServices
Advertisement